Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 53

1.

Caring for Patients With Advanced Cancer: The Role of the Chair, and Other Reflections From 3 Decades in the Clinic.

Tchekmedyian NS.

Oncology (Williston Park). 2015 Aug;29(8):537. No abstract available.

2.

Physical function and quality of life in frail and/or elderly patients with metastatic colorectal cancer treated with capecitabine and bevacizumab: an exploratory analysis.

Ward P, Hecht JR, Wang HJ, Dichmann R, Liem AK, Chan D, Patel R, Hu EH, Tchekmedyian NS, Wainberg ZA, Naeim A.

J Geriatr Oncol. 2014 Oct 1;5(4):368-75. doi: 10.1016/j.jgo.2014.05.002. Epub 2014 Jul 4.

PMID:
25002322
3.

A phase II trial of frontline capecitabine and bevacizumab in poor performance status and/or elderly patients with metastatic colorectal cancer.

Naeim A, Ward PR, Wang HJ, Dichmann R, Liem AK, Chan D, Patel R, Hu EH, Tchekmedyian NS, Wainberg ZA, Hecht JR.

J Geriatr Oncol. 2013 Oct;4(4):302-9. doi: 10.1016/j.jgo.2013.05.001. Epub 2013 Jun 7.

PMID:
24472472
4.

PR-104 a bioreductive pre-prodrug combined with gemcitabine or docetaxel in a phase Ib study of patients with advanced solid tumours.

McKeage MJ, Jameson MB, Ramanathan RK, Rajendran J, Gu Y, Wilson WR, Melink TJ, Tchekmedyian NS.

BMC Cancer. 2012 Oct 25;12:496. doi: 10.1186/1471-2407-12-496.

5.
6.

Phase II trial of weekly patupilone in patients with castration-resistant prostate cancer.

Hussain A, DiPaola RS, Baron AD, Higano CS, Tchekmedyian NS, Johri AR.

Ann Oncol. 2009 Mar;20(3):492-7. doi: 10.1093/annonc/mdn665. Epub 2008 Dec 15.

PMID:
19087985
7.

Hemoglobin increase is associated with improved health-related quality of life in patients with cancer not receiving chemotherapy.

Smith JR, Glaspy JA, Tchekmedyian NS, Austin MD, Kallich JD.

Support Cancer Ther. 2003 Oct 1;1(1):49-54. doi: 10.3816/SCT.2003.n.004.

PMID:
18628131
8.

A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer.

Small EJ, Tchekmedyian NS, Rini BI, Fong L, Lowy I, Allison JP.

Clin Cancer Res. 2007 Mar 15;13(6):1810-5.

9.

Resource utilisation and time commitment associated with correction of anaemia in cancer patients using epoetin alfa.

Meehan KR, Tchekmedyian NS, Smith RE, Kallich J.

Clin Drug Investig. 2006;26(10):593-601.

PMID:
17163293
10.

Treating the anorexia/cachexia syndrome.

Tchekmedyian NS.

J Support Oncol. 2006 Nov-Dec;4(10):506-7. No abstract available.

PMID:
17136865
11.

Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer.

Abou-Alfa GK, Letourneau R, Harker G, Modiano M, Hurwitz H, Tchekmedyian NS, Feit K, Ackerman J, De Jager RL, Eckhardt SG, O'Reilly EM.

J Clin Oncol. 2006 Sep 20;24(27):4441-7.

PMID:
16983112
12.

Clinical benefit of zoledronic acid in patients with lung cancer and other solid tumors: analysis based on history of skeletal complications.

Hirsh V, Tchekmedyian NS, Rosen LS, Zheng M, Hei YJ.

Clin Lung Cancer. 2004 Nov;6(3):170-4.

PMID:
15555218
13.

Role of dendritic cell phenotype, determinant spreading, and negative costimulatory blockade in dendritic cell-based melanoma immunotherapy.

Ribas A, Glaspy JA, Lee Y, Dissette VB, Seja E, Vu HT, Tchekmedyian NS, Oseguera D, Comin-Anduix B, Wargo JA, Amarnani SN, McBride WH, Economou JS, Butterfield LH.

J Immunother. 2004 Sep-Oct;27(5):354-67.

PMID:
15314544
14.

Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial.

Rosen LS, Gordon D, Tchekmedyian NS, Yanagihara R, Hirsh V, Krzakowski M, Pawlicki M, De Souza P, Zheng M, Urbanowitz G, Reitsma D, Seaman J.

Cancer. 2004 Jun 15;100(12):2613-21.

15.

A Phase II trial of vinorelbine tartrate in patients with disseminated malignant melanoma and one prior systemic therapy: a Southwest Oncology Group study.

Whitehead RP, Moon J, McCachren SS, Hersh EM, Samlowski WE, Beck JT, Tchekmedyian NS, Sondak VK; Southwest Oncology Group.

Cancer. 2004 Apr 15;100(8):1699-704.

16.

The relationship between psychologic distress and cancer-related fatigue.

Tchekmedyian NS, Kallich J, McDermott A, Fayers P, Erder MH.

Cancer. 2003 Jul 1;98(1):198-203.

17.

A dose- and schedule-finding study of darbepoetin alpha for the treatment of chronic anaemia of cancer.

Smith RE Jr, Tchekmedyian NS, Chan D, Meza LA, Northfelt DW, Patel R, Austin M, Colowick AB, Rossi G, Glaspy J.

Br J Cancer. 2003 Jun 16;88(12):1851-8.

18.

Darbepoetin alfa administered every 2 weeks alleviates anemia in cancer patients receiving chemotherapy.

Glaspy JA, Tchekmedyian NS.

Oncology (Williston Park). 2002 Oct;16(10 Suppl 11):23-9.

19.

Psychological outcomes associated with anemia-related fatigue in cancer patients.

Kallich JD, Tchekmedyian NS, Damiano AM, Shi J, Black JT, Erder MH.

Oncology (Williston Park). 2002 Sep;16(9 Suppl 10):117-24. Review.

20.

Anemia in cancer patients: significance, epidemiology, and current therapy.

Tchekmedyian NS.

Oncology (Williston Park). 2002 Sep;16(9 Suppl 10):17-24. Review.

21.

Darbepoetin alfa given every 1 or 2 weeks alleviates anaemia associated with cancer chemotherapy.

Glaspy JA, Jadeja JS, Justice G, Kessler J, Richards D, Schwartzberg L, Tchekmedyian NS, Armstrong S, O'Byrne J, Rossi G, Colowick AB.

Br J Cancer. 2002 Jul 29;87(3):268-76.

22.

Thalidomide and irinotecan-associated diarrhea.

Tchekmedyian NS.

Am J Clin Oncol. 2002 Jun;25(3):324. No abstract available.

PMID:
12040298
23.

Re-validation and shortening of the Functional Assessment of Anorexia/Cachexia Therapy (FAACT) questionnaire.

Ribaudo JM, Cella D, Hahn EA, Lloyd SR, Tchekmedyian NS, Von Roenn J, Leslie WT.

Qual Life Res. 2000;9(10):1137-46.

PMID:
11401046
24.

Novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia of chronic disease associated with cancer.

Smith RE Jr, Jaiyesimi IA, Meza LA, Tchekmedyian NS, Chan D, Griffith H, Brosman S, Bukowski R, Murdoch M, Rarick M, Saven A, Colowick AB, Fleishman A, Gayko U, Glaspy J.

Br J Cancer. 2001 Apr;84 Suppl 1:24-30.

25.

A Comparison of Oral Ondansetron and Intravenous Granisetron for the Prevention of Nausea and Emesis Associated with Cisplatin-Based Chemotherapy.

Spector JI, Lester EP, Chevlen EM, Sciortino D, Harvey JH, Whaley W, Madajewicz S, Isaacs R, Homesley HD, Yee S, Beck TM, Tchekmedyian NS, Crawford KH, Ames M, Creed MR.

Oncologist. 1998;3(6):432-438.

26.

Pharmacoeconomics of nutritional support in cancer.

Tchekmedyian NS.

Semin Oncol. 1998 Apr;25(2 Suppl 6):62-9.

PMID:
9625386
27.

Costs and benefits of nutrition support in cancer.

Tchekmedyian NS.

Oncology (Williston Park). 1995 Nov;9(11 Suppl):79-84. Review.

28.

Oral ondansetron for the control of cisplatin-induced delayed emesis: a large, multicenter, double-blind, randomized comparative trial of ondansetron versus placebo.

Navari RM, Madajewicz S, Anderson N, Tchekmedyian NS, Whaley W, Garewal H, Beck TM, Chang AY, Greenberg B, Caldwell KC, et al.

J Clin Oncol. 1995 Sep;13(9):2408-16.

PMID:
7666101
29.

Megestrol acetate in patients with AIDS-related cachexia.

Von Roenn JH, Armstrong D, Kotler DP, Cohn DL, Klimas NG, Tchekmedyian NS, Cone L, Brennan PJ, Weitzman SA.

Ann Intern Med. 1994 Sep 15;121(6):393-9.

PMID:
7794302
30.

Clinical approaches to nutritional support in cancer.

Tchekmedyian NS.

Curr Opin Oncol. 1993 Jul;5(4):633-8. Review.

PMID:
8364079
31.

Treatment of anorexia with megestrol acetate.

Tchekmedyian NS.

Nutr Clin Pract. 1993 Jun;8(3):115-8. Review.

PMID:
8289758
32.

Efficacy of oral ondansetron in the prevention of emesis in outpatients receiving cyclophosphamide-based chemotherapy. The Ondansetron Study Group.

Beck TM, Ciociola AA, Jones SE, Harvey WH, Tchekmedyian NS, Chang A, Galvin D, Hart NE.

Ann Intern Med. 1993 Mar 15;118(6):407-13.

PMID:
8439113
33.

Nutrition in advanced cancer: anorexia as an outcome variable and target of therapy.

Tchekmedyian NS, Halpert C, Ashley J, Heber D.

JPEN J Parenter Enteral Nutr. 1992 Nov-Dec;16(6 Suppl):88S-92S. Review.

PMID:
1287231
34.

Hormonal and metabolic abnormalities in the malnourished cancer patient: effects on host-tumor interaction.

Heber D, Byerley LO, Tchekmedyian NS.

JPEN J Parenter Enteral Nutr. 1992 Nov-Dec;16(6 Suppl):60S-64S. Review.

PMID:
1287226
35.

Megestrol acetate in cancer anorexia and weight loss.

Tchekmedyian NS, Hickman M, Siau J, Greco FA, Keller J, Browder H, Aisner J.

Cancer. 1992 Mar 1;69(5):1268-74.

PMID:
1739926
36.

Assessment and maintenance of nutrition in older cancer patients.

Tchekmedyian NS, Zahyna D, Halpert C, Heber D.

Oncology (Williston Park). 1992 Feb;6(2 Suppl):105-11. Review.

PMID:
1532723
37.

Clinical aspects of nutrition in advanced cancer.

Tchekmedyian NS, Zahyna D, Halpert C, Heber D.

Oncology. 1992;49 Suppl 2:3-7. Review.

PMID:
1461624
38.

Pathophysiology of cancer: hormonal and metabolic abnormalities.

Heber D, Tchekmedyian NS.

Oncology. 1992;49 Suppl 2:28-31. Review.

PMID:
1461623
39.

Overview of hormonal therapy in advanced breast cancer.

Tchekmedyian NS.

Oncology. 1992;49 Suppl 2:1-2. No abstract available.

PMID:
1461619
40.

A phase I/II study of high-dose megestrol acetate in the treatment of metastatic breast cancer.

Parnes HL, Abrams JS, Tchekmedyian NS, Tait N, Aisner J.

Breast Cancer Res Treat. 1991 Aug;18(3):171-7.

PMID:
1756260
41.

Treatment of anorexia and weight loss with megestrol acetate in patients with cancer or acquired immunodeficiency syndrome.

Tchekmedyian NS, Hickman M, Heber D.

Semin Oncol. 1991 Feb;18(1 Suppl 2):35-42.

PMID:
1992535
42.

Appetite stimulation and weight gain with megestrol acetate.

Aisner J, Parnes H, Tait N, Hickman M, Forrest A, Greco FA, Tchekmedyian NS.

Semin Oncol. 1990 Dec;17(6 Suppl 9):2-7.

PMID:
2259925
43.

Treatment of cancer anorexia with megestrol acetate: impact on quality of life.

Tchekmedyian NS, Hickman M, Siau J, Greco A, Aisner J.

Oncology (Williston Park). 1990 May;4(5):185-92; discussion 194.

PMID:
2143402
44.

High-dose megestrol acetate in the treatment of advanced breast cancer.

Tchekmedyian NS, Tait N, Abrams J, Aisner J.

Semin Oncol. 1988 Apr;15(2 Suppl 1):44-9.

PMID:
3368800
45.

Studies of high-dose megestrol acetate: potential applications in cachexia.

Aisner J, Tchekmedyian NS, Tait N, Parnes H, Novak M.

Semin Oncol. 1988 Apr;15(2 Suppl 1):68-75. Review.

PMID:
3285486
46.

Phase II study of N-methylformamide in patients with advanced colorectal cancer.

Tchekmedyian NS, Kaplan RS, Eisenberger M, Abrams J, Van Echo D.

Cancer Treat Rep. 1987 May;71(5):541-2. No abstract available.

PMID:
3567980
47.

High-dose megestrol acetate for the treatment of advanced breast cancer: dose and toxicities.

Aisner J, Tchekmedyian NS, Moody M, Tait N.

Semin Hematol. 1987 Apr;24(2 Suppl 1):48-55.

PMID:
3589708
48.

High-dose megestrol acetate. A possible treatment for cachexia.

Tchekmedyian NS, Tait N, Moody M, Aisner J.

JAMA. 1987 Mar 6;257(9):1195-8.

PMID:
3806918
49.

Appetite stimulation with megestrol acetate in cachectic cancer patients.

Tchekmedyian NS, Tait N, Moody M, Greco FA, Aisner J.

Semin Oncol. 1986 Dec;13(4 Suppl 4):37-43.

PMID:
3798127
50.

High-dose megestrol acetate in the treatment of postmenopausal women with advanced breast cancer.

Tchekmedyian NS, Tait N, Aisner J.

Semin Oncol. 1986 Dec;13(4 Suppl 4):20-5.

PMID:
3798125

Supplemental Content

Loading ...
Support Center